Heart and Blood Diseases

All Conditions

Neoplasms

Nervous System Diseases

Diseases and Abnormalities at or Before Birth

Symptoms and General Pathology

Rare Diseases

Thrombosis

Brain Neoplasms

Stroke

Aneurysm

Arteriovenous Malformations

Congenital Abnormalities

Constriction, Pathologic

Carotid Stenosis

Intracranial Arteriovenous Malformations

Sinus Thrombosis, Intracranial

Cavernous Sinus Thrombosis

Intracranial Aneurysm

Vascular Diseases

Embolism

Embolism and Thrombosis

Brain Diseases

Central Nervous System Diseases

Cerebrovascular Disorders

Carotid Artery Diseases

Arterial Occlusive Diseases

Vascular Malformations

Cardiovascular Abnormalities

Intracranial Arterial Diseases

Intracranial Thrombosis

Intracranial Embolism

Intracranial Embolism and Thrombosis

Thromboembolism

Central Nervous System Vascular Malformations

Nervous System Malformations

Syndrome

Acute Graft Versus Host Disease

Intracranial Arteriovenous Malformation

Anti-Infective Agents

All Drugs and Chemicals

Metronidazole

The procedure will be done using standard criteria as per operator preference. All interventional cases at our institution undergo a "radial first" approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr).

Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a "radial first" approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr).

Transradial approach

Priyank Khandelwal, MD

The main objective of this single arm study is to evaluate the safety and feasibility of the AXS Infinity LS (Stryker, Freemont, CA, USA) and AXS Infinity LS Plus (Stryker, Freemont, CA, USA) catheters during the transradial approach through a secondary use of the data collected during neurointerventional procedures. This includes evaluating the conversion rates to a transfemoral approach. A secondary aim of the study is to assess the radial artery occlusion rates post procedure.

Patients who are undergoing endovascular intervention will be enrolled into the study. Consent will be obtained for the procedure and for the use of their prospectively collected clinical data. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a "radial first" approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr). If the artery does not meet the size criteria, only a 6Fr sheath will be used, and the data recorded during the procedure will not be utilized for analysis in this study. The preoperative and postoperative care will be the same for all the patients. No tests will be done outside of standard of care.

Safety and Feasibility of the Infinity Catheter for Radial Access

Safety and Feasibility of the Infinity Guide Catheter for Neuro Interventional Procedures Using Transradial Access

The size of the radial artery will be measured and the transradial approach will be used. Notation will be also be recorded if conversion to TFA is used.

Patient demographics will be analyzed such as past medical history, HTN, HLD, Afib

Rutgers, The State University of New Jersey

Assistant Professor

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Nasopharyngeal Carcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pathological Conditions, Anatomical

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Lipid Regulating Agents

Bone Density Conservation Agents

Calcium

Atorvastatin

Calcium, Dietary

Anticholesteremic Agents

Hypolipidemic Agents

Antimetabolites

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Enzyme Inhibitors

Patients will take atorvastatin 20mg per night, totally 2 years.

Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.

Patients in this group will take 20mg per night.

Placebo

Ying Peng, Ph.D

Patients with head and neck cancer who underwent irradiation have a higher risk of developing severe carotid stenosis, and eventually develop to transient ischemic attack or stroke. However, it's still not clear whether early intervene in vascular risk factors is benefit for patients after radiotherapy.

Our study aimed to evaluate the feasibility and safety of atorvastatin for preventing NPC patients after radiotherapy from severe carotid stenosis. In a randomized, double-blind, placebo-controlled trial, about 324 nasopharyngeal carcinoma (NPC) patients will be enrolled from six centers in Guangdong Province and randomized 1:1 to atorvastatin group or placebo group.

It is a randomized, double-blind, placebo-controlled trial, about 324 nasopharyngeal carcinoma (NPC) patients will be enrolled from six centers in Guangdong Province and randomized 1:1 to atorvastatin group (20mg per night, totally 2 years) or placebo group. All Patients will be followed up for 2 years. Ultrasound and Transcranial Color Doppler (TCD) will be used to evaluate the changes of intima-media thickness (IMT) and occurrence of plaque formation of carotid arteries. Safety will be monitored every 6 months.

Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis

Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis: A Multicenter, Double-blind, Placebo-Controlled, Randomized Trial

Patients will take Ultrasound and Transcranial Color Doppler every 6 months to measure the thickness of intima-media thickness (IMT) and occurrence of plaque formation of carotid arteries. We will compare the maximal IMT of bilateral carotid arteries at 2 years from baseline.

Patients will be followed up for 2 years. We defined sever carotid stenosis as stenosis\>50% by using ultrasound and TCD.

Patients will be followed up for 2 years and cardiovascular events such as stroke, transient ischemic attack (TIA) will be recorded.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Professer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety and Feasibility of the Infinity Catheter for Radial Access	NCT04553549	Brain Tumor Stroke, Acute Brain Aneurysm Intracranial Ar... Carotid Stenosi... Cavernous Sinus...	Transradial app...	18 Years -	Rutgers, The State University of New Jersey
Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis	NCT02022293	Nasopharyngeal ... Radiation Thera...	Atorvastatin Placebo	40 Years - 65 Years	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis	NCT02022293	Nasopharyngeal ... Radiation Thera...	Atorvastatin Placebo	40 Years - 65 Years	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Safety and Feasibility of the Infinity Catheter for Radial Access	NCT04553549	Brain Tumor Stroke, Acute Brain Aneurysm Intracranial Ar... Carotid Stenosi... Cavernous Sinus...	Transradial app...	18 Years -	Rutgers, The State University of New Jersey

Spots Global Cancer Trial Database for carotid stenosis